Objective: To investigate CSF biomarkers in presymptomatic and symptomatic mutation carriers with hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D), a model for sporadic cerebral amyloid angiopathy, and to determine the earliest deposited form of b-amyloid (Ab).
Sporadic cerebral amyloid angiopathy (sCAA) is a major cause of intracerebral hemorrhage (ICH), especially in the elderly. sCAA is caused by vascular accumulation of b-amyloid (Ab), but much remains unknown about its underlying pathophysiology. 1 Although clinical criteria for the diagnosis exist (the Boston criteria based on CAA-related hemorrhagic lesions on neuroimaging), 2 the definite diagnosis of sCAA can be established only postmortem or by brain biopsy, which hampers research on this disease. 3 Recognizing CAA in an early stage could limit bleeding complications by avoiding anticoagulation therapy or thrombolysis 4 and could provide insights into the preclinical pathophysiology of CAA, knowledge needed for designing future preventive trials. Hereditary cerebral hemorrhage with amyloidosis-Dutch type (HCHWA-D) provides a unique opportunity to study the preclinical phase of CAA. The underlying pathology of amyloid deposition is likely similar to that of sCAA. 5 In HCHWA-D, Ab accumulation is caused by a point mutation at codon 693 of the amyloid precursor protein (APP) gene located on chromosome 21, producing symptomatic disease with essentially 100% clinical penetrance. HCHWA-D can therefore be diagnosed by genetic analysis in presymptomatic individuals. 6 Direct measurement of Ab may identify early stages of CAA development. While in Alzheimer disease senile plaques in the brain parenchyma consist mainly of Ab 42 , vascular deposits contain mostly Ab 40 . 7, 8 In Alzheimer disease, decreased concentrations of Ab 42 and elevated concentrations of total tau (t-tau) and phosphorylated tau (p-tau) have been detected in the CSF. 9 In patients with sCAA with advanced vascular damage, decreased CSF Ab 42 and Ab 40 and mildly elevated t-tau and p-tau concentrations have been found. 10, 11 We aimed to find biomarkers of the earliest, potentially reversible phases of CAA. We investigated whether altered CSF levels of Ab and tau species are detectable in presymptomatic and symptomatic hereditary CAA mutation carriers.
METHODS Study design and participants. Patients and controls participated in the larger EDAN (Early Diagnosis of Amyloid Angiopathy Network) study, a collaboration among the Leiden University Medical Center (LUMC), Massachusetts General Hospital in Boston, and Erasmus University Medical Center in Rotterdam. The general aim of the study is to identify early biomarkers of CAA. In the LUMC, a cross-sectional study was performed to detect early MRI markers in HCHWA-D mutation carriers. In addition to MRI, all LUMC participants were asked to undergo a lumbar puncture.
Inclusion criteria for the LUMC EDAN study were age $18 years; diagnosis of HCHWA-D, family history of HCHWA-D, or willing to participate as control; able and willing to provide written informed consent; no contraindications for MRI.
In all participants, genetic testing was performed for the mutation in the APP gene. 6 After DNA was isolated from blood samples, the APP mutation test was performed with APP PCR and sequencing. 6 Because both mutation-positive and -negative participants were enrolled, at-risk individuals who did not wish to know their genetic status could still participate in the EDAN study without learning their mutation status.
HCHWA-D mutation carriers were divided into a symptomatic and a presymptomatic group. Symptomatic participants with HCHWA-D were defined as mutation carriers who had previously developed one or multiple clinical ICHs, of which at least one caused clinical symptoms and was confirmed by CT or MRI. Presymptomatic carriers were defined as participants without previous symptomatic ICH. EDAN controls were genetically negative controls and were mainly spouses or family members who did not carry the APP mutation.
CSF samples from additional controls of a similar age were obtained from the Radboud University Nijmegen Medical Center (RUNMC). These controls were 18-to 79-year-old individuals who visited the neurology outpatient clinic of the RUNMC for various reasons but had no neurologic diagnosis after the diagnostic workup. CSF samples were obtained as part of the clinical diagnostic workup. Samples were coded and used with the consent of the patients. Their CSF samples contained normal leukocyte and erythrocyte counts, normal glucose and lactate levels, normal total protein, and no oligoclonal immunoglobulin G bands. The data of the RUNMC controls .50 years of age have been previously published. 10 We divided the controls into those ,50 years and those $50 years of age. For both the EDAN participants and the additional RUNMC controls, demographic data were collected. EDAN participants underwent a neurologic examination by a neurologist (M.J.H.W. or G.M.T.), including the NIH Stroke Scale and modified Rankin Scale. Microbleeds were identified on T2* and defined as punctate, hypointense foci (,5 mm in diameter) involving the cortex, distinct from vascular flow voids. 12 and cortical superficial siderosis (cSS), which was defined as linear gyriform hypointensities 13 scored as absent or present. Enlarged perivascular spaces (EPVSs) were rated on T2-weighted sequences according to the STRIVE (Standards for Reporting Vascular Changes on Neuroimaging) recommendations 14 in the centrum semiovale and basal ganglia and, in line with previous studies, 15, 16 dichotomized as low (,20) or high (.20). White matter hyperintensity was defined as areas of increased signal intensity within the white matter on both fluid-attenuated inversion recovery and T2-weighted images. White matter hyperintensity volume was measured semiautomatically as previously described. 17 CSF analysis. For the CSF study described here, we included all participants who consented to undergo a lumbar puncture under standardized conditions. CSF samples of all participants were obtained with the same protocol. We collected CSF in polypropylene tubes, transferred the samples to laboratories within 30 minutes at 4 8 C, centrifuged them (622g for 5 minutes at 4 8 C-8 8 C), and stored the samples in polypropylene aliquots at 280 8 C. CSF was analyzed for Ab 40 , Ab 42 , t-tau, and p-tau 181 . All analyses were performed in the RUNMC with an ELISA as described previously (all from Innogenetics NV, Gent, Belgium). 18 We performed standard CSF analysis, including leukocyte count, erythrocyte count, total protein, and glucose. A leucocyte count #4/mL, red blood cells ,1,500/mL, total protein ,700 mg/L, and glucose ,4.3 mmol/L were considered normal. CSF results from the RUNMC and EDAN controls did not differ significantly. Personnel performing the analyses were blinded to clinical diagnosis.
Statistical analyses. We compared CSF concentrations and the Ab 40 /Ab 42 ratios between patients with HCHWA-D and controls, as well as the presence of cSS and high number of EPVSs, using the Mann-Whitney test. We compared presymptomatic mutation carriers with controls ,50 years old and symptomatic mutation carriers with controls $50 years old. To correct for the remaining age effect, we performed multivariate linear regression analyses for CSF values (square root transformed) with age as a covariate and a categorical variable with 3 levels (presymptomatic vs symptomatic vs controls) as a factor. Multivariate linear regression correcting for age was used to assess the correlation between CSF levels, microbleed count, and white matter hyperintensity volume in mutation carriers. Microbleed count was transferred logarithmically (in case of zero microbleeds, the log[microbleeds] was set at zero). To look at the correlation between age, Ab 40 , and Ab 42 , scatterplots with separate regression lines for mutation carriers and controls were plotted. Intercepts at the mean age of the study population and the slopes of the regression lines were compared with the use of a multivariate linear regression model. RESULTS Between January 2013 and April 2014, 57 participants were enrolled in the EDAN study at the LUMC. Twenty-five of the 57 participants gave consent for a lumbar puncture. Of these, 5 were presymptomatic HCHWA-D mutation carriers, 11 were symptomatic mutation carriers, and 9 were controls. CSF samples of 73 additional controls from the RUNMC were collected.
Presymptomatic carriers had a mean age of 36 6 13 years and were all women (table 1). None of them had neurologic or cognitive symptoms. One presymptomatic patient had 32 lobar microbleeds on 3T MRI and one slightly larger (5.4 3 3.5 mm), asymptomatic hemorrhage in the right occipital lobe. The other 4 participants had no microbleeds and only a little white matter hyperintensity volume (median 1 mL). Presymptomatic mutation carriers who did not undergo a lumbar puncture were slightly younger (mean age 33 years) and were more often men (M/F 3/4 vs 0/5) compared with presymptomatic carriers who did participate in the CSF substudy.
Symptomatic carriers had a mean age of 55 6 6 years and an equal sex distribution. One symptomatic carrier was excluded from the analysis because of a high erythrocyte count. All symptomatic carriers had at least one symptomatic ICH confirmed by previous MRI (6 carriers had .1 ICH). They had a median NIH Stroke Scale score of 2, a median modified Rankin Scale score of 3, and a median Mini-Mental State Examination score of 27 (table  1) . Symptomatic carriers who did not undergo lumbar puncture did not differ in age or sex distribution Table 1 Clinical characteristics from symptomatic carriers who participated in the CSF study.
In total, 31 participants were included in the control group ,50 years old (mean age 31 6 7 years) and 50 in the control group $50 years of age (mean age 61 6 8 years). One EDAN control $50 years of age was excluded from the analyses because of a high total protein in the CSF. to symptomatic HCHWA-D mutation carriers (6.2 vs 4.8; p 5 0.18).
In symptomatic HCHWA-D mutation carriers, CSF t-tau (p 5 0.040, figure 1C ) and CSF p-tau 181 (p 5 0.011, figure 1D ) concentrations were decreased compared with controls $50 years of age. After correction for age, this difference was not significant for t-tau (p 5 0.061) but remained significant for p-tau 181 (p 5 0.025). In presymptomatic HCHWA-D carriers, there was no difference in the levels of tau protein ( figure 1, C and D) . The levels of p-tau 181 and t-tau were not different between presymptomatic and symptomatic mutation carriers. Ab is secreted by neurons and transported along the perivascular and glymphatic pathways to the subarachnoid space. 19 The perivascular pathway transports Ab via the interstitial fluid toward the cerebral vasculature. Because CAA is caused by Ab accumulation in the vessel wall, 20 the perivascular pathway is most likely involved in CAA pathophysiology. 21 Two previous studies in patients with sporadic CAA also demonstrated decreased CSF Ab 40 and Ab 42 levels. 10, 11 However, in this study, the reduction in Ab 40 and Ab 42 was more pronounced, most likely because of the more severe phenotype of HCHWA-D. 22 Reduction in both CSF Ab 40 and 8 Our data hinted at the possibility that presymptomatic patients had relatively greater reductions in Ab 42 (55% of control values) than Ab 40 (75% of control values; figure 1 and table 2). This observation (which will require larger numbers of participants to confirm) likely relates to reports that in the process of Ab accumulation in the vessel wall, Ab 42 deposits earlier than Ab 40 . 23, 24 Ab 42 is believed to seed in the vessels, followed by growth of these deposits by Ab 40 deposition, leading to vessel pathology. 23, [25] [26] [27] Because HCHWA-D is a dominantly inherited disorder, mutation carriers are heterozygous and produce both wild-type Ab and mutant Dutch Ab. 28 The assays used in this study, however, measured total amounts of CSF Ab. Future studies are needed to separately identify the amounts of wild-type and Dutch Ab present in the CSF of patients with HCHWA-D.
It has been hypothesized that Ab-related pathology in Alzheimer disease starts decades before clinical symptoms appear. The Dominantly Inherited Alzheimer Network (DIAN) investigated CSF markers in carriers and noncarriers of autosomal dominant Alzheimer disease. Because the age at symptom onset is similar between generations, it can be estimated for presymptomatic mutation carriers. 29 The DIAN studies showed that in mutation carriers Ab 42 starts to decline z25 years before the expected symptom onset. 30 Although the age at onset in patients with HCHWA-D is not consistent within families, most mutation carriers develop their first ICH between 45 and 60 years of age. 31 Because the group of presymptomatic HCHWA-D carriers had a mean age of 36 years, our results suggest that abnormal Ab levels can be detected in the CSF at least 10 years before the disease symptoms manifest. The youngest presymptomatic mutation carrier with decreased Ab concentrations was in the early 20s.
Increasing microbleed count, increasing white matter hyperintensity volume, and the presence of superficial siderosis were associated with decreasing CSF Ab 40 and Ab 42 levels. In the 4 presymptomatic carriers without microbleeds, with minimal white matter hyperintensity volume, and without indications for cSS, the CSF Ab 40 and Ab 42 levels were also decreased. This suggests that decreased CSF Ab levels can be measured before radiologic markers of CAA can be found and may be good biomarkers for the earlier stages of CAA. Furthermore, Ab 40 was significantly associated with increasing microbleed count and increasing white matter hyperintensity volume independently of age.
We found significantly lower CSF p-tau 181 concentrations only in symptomatic mutation carriers, after correction for age, albeit with complete overlap in the data points. Previous studies showed mildly increased levels of tau species in participants with sCAA compared with controls, although the levels were lower than in participants with Alzheimer disease. 10, 11 In Alzheimer disease, elevated CSF t-tau and p-tau 181 concentrations are presumably related to the formation of neurofibrillary tangles, although elevated tau species also might represent a nonspecific axonal injury. 32 The finding of elevated CSF tau levels in patients with sCAA might represent mixed CAA and Alzheimer pathology. In HCHWA-D, however, neuropathologic examination revealed no neurofibrillary tangles, 33, 34 consistent with the current CSF results. Taken together, these data suggest that HCHWA-D represents a pure form of CAA pathology without accompanying tau pathology.
The main limitation of this study is the relatively small sample size, which, however, reflects the limited number of available patients with HCHWA-D for in vivo examinations. Despite the small number of patients, we could still demonstrate significant differences in CSF Ab biomarkers. Furthermore, the definition of presymptomatic and symptomatic patients, based solely on a symptomatic ICH, is debatable. Occasionally, patients with HCHWA-D experience cognitive decline before their first ICH. 31 Additionally, small ICHs might occur without obvious clinical symptoms. In this study, only one presymptomatic mutation carrier showed multiple microbleeds and one slightly larger, asymptomatic hemorrhage. Still, none of the presymptomatic carriers demonstrated neurologic or cognitive symptoms. Lastly, our controls were derived from 2 different studies, the EDAN study and a cohort from RUNMC. However, all samples were handled the same and were analyzed in one laboratory using standardized techniques. Furthermore, CSF results did not differ significantly. For the RUNMC control group, no MRI scans were available. Therefore, we cannot rule out that some controls might have preclinical sCAA, although the controls were known to be without a clinical neurologic disorder. In addition, any undetected sCAA in the RUNMC controls would be expected to bias toward a null result for comparisons with participants with HCHWA-D.
In this hereditary form of CAA, both CSF Ab 40 and Ab 42 concentrations are markers of the earliest phase of CAA-related pathology before clinical or radiologic findings appear. This finding provides insight into the pathogenesis of CAA and provides important information for future trials aimed at preventing CAA-related ICH. Longitudinal studies in this unique hereditary CAA group will help to further unravel the dynamics of CSF biomarkers over time and their relationship to disease progression.
